Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome

AIM： To determine whether Lactobacillus casei strain Shirota （Yakult） can alter small intestinal bacterial overgrowth （SIBO）, as tested by the lactulose breath test, and whether this is associated with changes in symptoms in irritable bowel syndrome （IBS）. METHODS： 18 patients with IBS （Rome Ⅱ crite...

Full description

Saved in:
Bibliographic Details
Published in:World journal of gastroenterology : WJG 2008-08, Vol.14 (32), p.5020-5024
Main Authors: Barrett, Jacqueline S, Canale, Kim E K, Gearry, Richard B, Irving, Peter M, Gibson, Peter R
Format: Article
Language:English
Subjects:
Adult
Aged
Breath Tests
Female
Fermentation
Humans
Irritable Bowel Syndrome - microbiology
Irritable Bowel Syndrome - therapy
Lactobacillus casei
Male
Middle Aged
Probiotics - administration & dosage
Rapid Communication
功能性消化障碍
小肠细菌繁殖
急性肠炎
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:AIM： To determine whether Lactobacillus casei strain Shirota （Yakult） can alter small intestinal bacterial overgrowth （SIBO）, as tested by the lactulose breath test, and whether this is associated with changes in symptoms in irritable bowel syndrome （IBS）. METHODS： 18 patients with IBS （Rome Ⅱ criteria）, who showed an early rise in breath hydrogen with lactulose （ERBHAL）, consumed 65 mL of Yakult daily for 6 wk. Lactulose breath test was repeated at the end of the treatment period. Symptoms were recorded daily using a 10 cm visual analogue scale. RESULTS： 14 patients completed the study, 9 （64%） had reversal of ERBHAL, with the median time of first rise in breath hydrogen increasing from 45 to 75 min （P = 0.03）. There was no significant improvement in the symptom score with probiotic therapy, except for wind （P = 0.04）. Patients commencing with at least moderate symptoms and who no longer had ERBHAL at the end of treatment, showed improvement in the overall symptoms scores [median final score 5.3 （IQR 3.9-5.9）, 55% reduction; n = 6] to a greater extent than those who had had persisting ERBHAL [final score 6.9 （5.0-7.0）, 12% reduction; n = 5; P = 0.18]. CONCLUSION： Yakult is effective in altering fermentation patterns in the small bowel, consistent with reducing SIBO. The loss of ERBHAL was associated with reduced symptoms. The true interpretation of these findings awaits a randornised, controlled trial.
ISSN:1007-9327
2219-2840
DOI:10.3748/wjg.14.5020